College ter Beoordeling van Geneesmiddelen / Medicines Evaluation Board

Graadt van Roggenweg 500
3531 AH Utrecht
The Netherlands

DECENTRALISED PROCEDURE

PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT

Milteforan 20 mg/ml oral solution for dogs

PRODUCT SUMMARY

EU Procedure number	NL/V/0405/001
Name, strength and pharmaceutical form	Milteforan 20 mg/ml oral solution for dogs
Applicant	VIRBAC 1ère avenue 2065 m LID 06516 Carros France
Active substance(s)	Miltefosine
ATC Vetcode	QP51DX07
Target species	Dogs
Indication for use	Treatment of clinical signs of canine leishmaniasis, caused by *Leishmania infantum*

PRODUCT INFORMATION

The Summary of Product Characteristics (SPC), the labelling and package leaflet for this veterinary medicinal product (VMP) is available in the Union Product Database (UPD).

SUMMARY OF ASSESSMENT

Legal basis of original application*	Generic application in accordance with Article 18 of Regulation (EC) 2019/6 as amended.
Reference product (RP)	Milteforan
Marketing authorisation holder	Virbac
MS where the RP is or has been authorised	ES
Marketing authorisation number EU procedure number	ESP1761
Date of authorisation	July 2007
Date of completion of the original decentralised procedure	20 December 2023
Date veterinary medicinal product first authorised in the Reference Member State (MRP only)	
Concerned Member States for original procedure	BG, CY, EL, ES, FR, HR, IT, PT, RO, SI
Concerned Member States for subsequent recognition procedure	
Withdrawn CMS during original decentralised procedure	

*Please be aware that certain parts of the dossier may be varied and consequently be subject to protection of technical documentation – for these and other changes of referenceability to parts of the dossier, please see chapter POST-AUTHORISATION PROCEDURES

1. SCIENTIFIC OVERVIEW

The veterinary medicinal product (VMP) is produced and controlled using validated methods and tests, which ensure the consistency of the VMP released on the market.

It has been shown that the VMP can be safely used in the target species; the reactions observed are indicated in the SPC.

The VMP is safe for the user and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the VMP was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

2. QUALITY DOCUMENTATION (physicochemical, biological or microbiological information)

A. Product description

The VMP contains miltefosine (20 mg/ml) as the active substance and excipients (hydroxypropylcellulose, propylene glycol and purified water).

The container/closure system consists of 30, 60 and 90 ml bottles of White opaque polyethylene terephthalate (PET) bottles equipped with a sampling polypropylene (PP) snap cap with silicone stopper and a 3 mL polypropylene (PP) syringe placed in a carton box.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines. The choice of the formulation and the absence of preservative are justified.

B. Description of the manufacturing method

The VMP is manufactured fully in accordance with the principles of good manufacturing practice at a licensed manufacturing site.

The VMP is manufactured using conventional manufacturing techniques and consists of eight steps for formulation and sample collection, and two steps for filling.

Process validation for 3 full-scale batches has been performed. Each batch was packed in the 3 commercial containers.

C. Production and control of starting materials

The active substance is miltefosine, an established active substance that complies in-house specifications. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

Hydroxypropylcellulose, propylene glycol and purified water comply with the European Pharmacopoeia monographs currently in force 01/2005:0337, 01/2005:0430 and 01/2005:0008, respectively. A certificate of analysis has been submitted for a batch of each excipient.

Certificates of analysis for packaging materials including routine controls have been provided.

D. Control tests carried out on isolated intermediates during the manufacturing process

Not applicable

E. Control tests on the finished product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

The applicant has provided suitable results of a risk assessment to control the levels of elemental impurities in the proposed VMP.

F. Stability tests

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the VMP throughout its shelf life of 3 years under the approved conditions. Stability data has demonstrated a 12 weeks In-use shelf life.

G. Other information

None

3. SAFETY DOCUMENTATION (safety and residues tests)

As this is a generic application according to Article 18 of Regulation (EC) 2019/6 and essential similarity to a reference VMP has been demonstrated, results of safety test tests are not required.

The safety aspects of this VMP are identical to the reference VMP.

Warnings and precautions as listed on the product literature are the same as those of the reference VMP and supplemented with additional statements, based on increased knowledge and the current state of science. This information is considered adequate to ensure safety of the product to users and the environment.

A. Safety tests

User safety

The applicant has provided an extensive user risk assessment discussing all possible exposure scenario's.

The major risks for this product are skin and/or eye irritation.

Moreover, accidental ingestion by children when a filled syringe is left unattended.

Pregnant women should be recommended not to handle this product, as harmful effects to the foetus cannot be excluded.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the VMP.

Environmental Risk Assessment

A Phase I environmental risk assessment (ERA) was provided according to the CVMP/VICH guidelines.

Phase I:

The environmental risk assessment can stop in Phase I and no Phase II assessment is required because

The VMP will only be used in non-food animals.

4. EFFICACY DOCUMENTATION (preclinical studies and clinical trials)

As this is a generic application according to Article 18 of Regulation (EC) 2019/6 and essential similarity to a reference VMP has been demonstrated, efficacy studies are not required. The efficacy claims for this VMP are equivalent to those of the reference VMP.

Development of resistance and related risk in animals

Information on development of resistance was provided.

Adequate warnings and precautions appear on the product literature.

5. OVERALL CONCLUSION AND BENEFIT-RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the VMP is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the VMP for humans and the environment is acceptable.

POST-AUTHORISATION PROCEDURES

The SPC and package leaflet may be updated to include new information on the quality, safety and efficacy of the VMP. The current SPC is available in the Union Product Database (UPD).

This section contains information on significant changes, which have been made after the original procedure, which are important for the quality, safety or efficacy of the VMP.

None